




Sqi

DIAGNOSTICS

science quality innovation



FORWARD LOOKING STATEMENTS

This presentation may contain certain statements including, without limitation, the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “benefits”, “leading to”, “possible”, “is subject to” and other similar expressions which may constitute “forward-looking statements” within the meaning of applicable securities laws.

Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sell our products including our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business; the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits; adverse changes in general economic conditions; international risk and currency exchange fluctuations; competitor activity; technology changes; regulatory approvals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in the future.

Such statements, risks and uncertainties are detailed in the Company's ongoing filings with the securities regulatory authorities, and are available to the public at www.sedar.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

WHY INVEST...?

OVER THE
NEXT 5 YEARS

1. GROWTH IN SUSTAINABLE RECURRING REVENUE
2. CLIA LAB TESTING SERVICES ADDS A MULTIPLE TO OUR REVENUE PER SAMPLE FROM KITS SALES
3. GROWING A TEST-CENTRIC PORTFOLIO OF NEW PRODUCTS IN CLINICAL AND DTC MARKETS
4. COMMERCIALIZED PRODUCTS FOR CUSTOMERS TO EXCEED 2.5m TESTS PER YEAR
5. ACHIEVE CASH FLOW POSITIVE

AND, VALUATIONS IN THIS SECTOR CAN EXCEED 16X REVENUES
















**A DIAGNOSTIC TOOLS COMPANY OFFERING MULTIPLEXED DIAGNOSTIC TEST KITS AND
AUTOMATED SYSTEMS TO MEET THE UNMET NEEDS OF**


















DIAGNOSTIC COMPANIES WITH NOVEL TESTS & BIOPHARMA DRUG DEVELOPERS

- Proven multiplexing technology – more results, fewer tests run
- Growing list of established diagnostics and global biopharma customers
- Technical superiority
- Very high levels of customer satisfaction
- ISO 13485 compliant development and manufacturing – trust
- Achieving significant cost reductions in our customers' core business

EXPERIENCED EXECUTIVE TEAM


Name	Title	Previous Affiliations
Andrew Morris	CEO	   
Eric Brouwer	CSO	  
Russ Peloquin	VP, Sales & Marketing	 
Aye Nyein San	VP Engineering	  
Patricia Lie	VP Finance	TD Canada Trust PwC
Peter Lea	Founder	 45 Publications; 40 Patents

BOARD OF DIRECTORS = 66% OWNERSHIP

Name	Title	Affiliations
Clive Beddoe	Chairman	 Hanover Group of Companies
Gerald Connor	Board Member	 
Wilmot Matthews	Board Member	
Claude Ricks	Chairman, Audit Committee	   
Eric Schneider	Board Member	
Eric Zwisler	Board Member	  
Andrew Morris	Board Member, CEO	    

MULTIPLEXING IS WHAT WE DO

mul-ti-plex ---- verb ---- /'mæl-tē -, pleks/
-to detect multiple analytes from a single biological specimen



one well
one unit of effort
multiple results

the pain is cost,
the cure is multiplexing and automated analyzers from SQI

using only 15 minutes of labour, our products and systems
deliver full panels of over 7,000 quantified results
reducing labour costs by > 90%
maintaining quality and performance
in every result

SIGNIFICANT LABOUR AND TIME SAVINGS

10 UNIQUE RESULTS PER PATIENT SAMPLE

Standard ELISA
(semi-manual operation)



50 Minutes / Patient

10-
plex

sqidlite™



30 Seconds / Patient

Save time and reduce costs, with superior technical performance

SIGNIFICANT LABOUR AND TIME SAVINGS – MATH


10 biomarker panel

100,000 patient samples



Standard ELISA
(SEMI-manual operation)

10 blood samples / patient
20 if using duplicates
20,810 ELISA Kits
870 days of labour



sqidlite™
(fully automated operation)


1 small blood sample / patient
no duplicates needed
1,042 SQI Kits
34 days of labour on 2 sqidlites

and, the sqid**lite** is super easy to use

OUR PRODUCT PORTFOLIO

1

INSTRUMENTS



\$220k

FULLY AUTOMATED
75k-130k SAMPLES / YR



\$320k

FULLY AUTOMATED
+150k SAMPLES / YR



\$90k

semi AUTOMATED
100k SAMPLES / YR

2

KITS

Custom Diagnostics

Custom Pharma

FDA Cleared Tests

Off the Shelf Biomarkers

Drive Recurring Revenue

Portable Across
Instruments

Revenue of up to \$20 per
sample

3


SERVICES

RAPID KIT
DEVELOPMENT

PHARMA TESTING
SERVICES

CLIA TESTING
SERVICES (new!)

REVENUE TRAJECTORY SINCE FISCAL Q1 2018



- kits sales drive our business success with high margin revenue
- we have been driving consistent growth in kit sales

BLUE SKY OPPORTUNITY


BLUE SKY OPPORTUNITY					
		<i>Annualized Recurring Revenue Potential</i>			
Patient Samples tested per month		Clinical or Direct to Consumer Kits	CLIA Testing Services	TOTAL KIT REVENUE	
	10,000 --->	\$ 2,770,000	+	\$ 2,400,000	= \$ 5,170,000
	30,000 --->	\$ 7,480,000	+	\$ 7,200,000	= \$ 14,680,000
2024	50,000 --->	\$ 11,220,000	+	\$ 12,000,000	= \$ 23,220,000

- Positive cash flow driven by high margin kits sales

Focus on Two Major Dx Markets

Dx Target Markets Size Estimates **2017**

Global IVD Market	\$ 59 billion
US IVD Market Total (2017)	\$ 23 billion
Addressable Segments Estimate (Autoimmune, Cardiac, Inflammatory, Respiratory, Transplant, Other)	20%
Clinical Dx Reagents (Kits) as % of Total Market	66%



Addressable IVD Market for Kits	\$ 3.04 billion
Direct to Consumer Kits	\$ 350 million
Total	\$ 3.39 billion



North America Biopharma

Biopharma Drug Development Testing	\$ 11 billion
Reagents/Kits as % of Total Market	66%
Key SQI Addressable Segments (biomarkers, cytokines, immunogenicity)	33%
Addressable Biopharma	\$ 2.40 billion

PREDICTIVE HEALTH DIAGNOSTICS - CARDIAC PULS TEST = UNMET NEED

- 7 Plex panel for cardiac markers combined with a proprietary algorithm
- Test predicts with 80% confidence likelihood of an adverse cardiac event forward for five years
- Important as it provides forward-looking evidence to guide lifestyle changes or interventional treatment well ahead of an event
- Customer currently running tests at their CLIA lab in California
- SQI projected revenue to be ~\$ 15.00 per test with volumes of 10,000 samples per month exiting Q4 2019
- For more information go to www.pulstest.com



IMAWARE - DIRECT TO CONSUMER

NEW direct-to-consumer diagnostic testing market is predicted to grow to \$350M by the year 2020

- Direct to consumer strategy, large investment in on-line marketing, sales and fulfillment
- 2 sqidlites validated in Sept18
- SQI's celiac product launch Dec18
- Followed by celiac monitoring subscription launched Jan19
- SQI's rheumatoid arthritis product Jan19
- Follow-on products to be developed for imaware –cardiac health, men's health, other....
- A minimum number of kits to be purchased by imaware to maintain retail market exclusivity
- Celiac Disease affects at least 3 million Americans. It is the most common — and one of the most underdiagnosed -- hereditary autoimmune conditions in the United States today.
- Rheumatoid Arthritis which afflicts 1% of the world's population and where 1.3 million prescriptions will be written this year
- For more information go to imaware.health



WHY INVEST...?

OVER THE
NEXT 5 YEARS

1. GROWTH IN SUSTAINABLE RECURRING REVENUE
2. CLIA LAB TESTING SERVICES ADDS A MULTIPLE TO OUR REVENUE PER SAMPLE FROM KITS SALES
3. GROWING A TEST-CENTRIC PORTFOLIO OF NEW PRODUCTS IN CLINICAL AND DTC MARKETS
4. COMMERCIALIZED PRODUCTS FOR CUSTOMERS TO EXCEED 2.5m TESTS PER YEAR
5. ACHIEVE CASH FLOW POSITIVE

AND, VALUATIONS IN THIS SECTOR CAN EXCEED 16X REVENUES

COMPANY SNAPSHOT

TSX-V :SQD

Traded on OTCQ :SQIDF

Shares outstanding: 158M

Warrants: 106M

Stock Options Granted: 9.2M


Market Cap: ~\$12M

Insider ownership ~ 66%





SQI
DIAGNOSTICS



CONTACT INFORMATION:

SQI DIAGNOSTICS INC.

36 METEOR DRIVE

TORONTO, CANADA M9W 1A4

IR@SQIDIAGNOSTICS.COM/AMORRIS@SQIDIAGNOSTICS.COM

416-674-9500 /X229